Filtered By:
Cancer: Lymphoma
Drug: Dexamethasone
This page shows you your search results in order of date.
Order by Relevance | Date
Total 210 results found since Jan 2013.
Diosgenin prevents dexamethasone-induced myotube atrophy in C2C12 cells
Arch Biochem Biophys. 2023 Sep 16:109759. doi: 10.1016/j.abb.2023.109759. Online ahead of print.ABSTRACTSeveral pathophysiological abnormalities, including a sedentary lifestyle, chronic diseases, and oxidative stress, can contribute to muscle atrophy triggered by an imbalance in muscle protein synthesis and degradation. Resolving muscle atrophy is a critical issue as it can reduce the quality of life. Here, one of the promising functional food factors, diosgenin (a steroidal sapogenin) showed strong preventive activities against dexamethasone (Dex)-induced muscle atrophy, as determined by the expression levels and morphol...
Source: Archives of Biochemistry and Biophysics - September 18, 2023 Category: Biochemistry Authors: Yasukiyo Yoshioka Shiori Oishi Keita Onoda Katsumi Shibata Noriyuki Miyoshi Source Type: research
Real World Efficacy and Toxicity of Selinexor: Importance of Patient Characteristics, Dose Intensity and Post Progression Outcomes
CONCLUSION: In conclusion, selinexor-based therapy provides an additional treatment option in the real word setting and with appropriate dosing and toxicity management a subset of patients may have significant benefit.PMID:37599164 | DOI:10.1016/j.clml.2023.07.013
Source: Clinical Lymphoma and Myeloma - August 20, 2023 Category: Cancer & Oncology Authors: Efstathios Kastritis Maria Gavriatopoulou Eirini Solia Foteini Theodorakakou Vasiliki Spiliopoulou Panagiotis Malandrakis Ioannis Ntanasis-Stathopoulos Magdalini Migkou Nikoleta Kokkali Evangelos Eleutherakis-Papaiakovou Rodanthi Syrigou Despina Fotiou Ev Source Type: research
Venous Thromboembolism Risk in Patients With Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination With Lenalidomide and Dexamethasone
CONCLUSION: In this cohort, KRd was not associated with an increase in VTE risk compared to VRd, contrary to prior literature.PMID:37543510 | DOI:10.1016/j.clml.2023.07.009
Source: Clinical Lymphoma and Myeloma - August 5, 2023 Category: Cancer & Oncology Authors: Alexa J Loncharich Mark A Fiala Michael J Slade Angela Vickroy Margaret Kavanaugh Carmen Wilson Mark A Schroeder Keith Stockerl-Goldstein Ravi Vij Kristen M Sanfilippo Source Type: research
Isatuximab Plus Carfilzomib and Dexamethasone in East Asian Patients With Relapsed Multiple Myeloma: Updated IKEMA Subgroup Analysis
CONCLUSION: Based on the results of this analysis, Isa-Kd is a novel treatment option for East Asian patients with relapsed MM.PMID:37479547 | DOI:10.1016/j.clml.2023.06.011
Source: Clinical Lymphoma and Myeloma - July 21, 2023 Category: Cancer & Oncology Authors: Yawara Kawano Kihyun Kim Chang Ki Min Youngil Koh Kenichi Ishizawa Sung Hyun Kim Shigeki Ito Junji Tanaka Michihiro Uchiyama Tadao Ishida Jin Seok Kim Philippe Moreau Thomas Martin Keisuke Tada Marie-Laure Risse Kenshi Suzuki Source Type: research
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
Selinexor-Based Triplet Regimens in Patients With Multiple Myeloma Previously Treated With Anti-CD38 Monoclonal Antibodies
CONCLUSION: Selinexor-based regimens may offer effective and well-tolerated therapy to patients with relapsed and/or refractory MM who had disease previously exposed or refractory to αCD38 mAb therapy and could help address the unmet clinical need in these high-risk patients.PMID:37393120 | DOI:10.1016/j.clml.2023.06.001
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Gary J Schiller Brea C Lipe Nizar J Bahlis Sascha A Tuchman William I Bensinger Heather J Sutherland Suzanne Lentzsch Muhamed Baljevic Darrell White Rami Kotb Christine I Chen Adriana Rossi Noa Biran Richard LeBlanc Sebastian Grosicki Maurizio Martelli Eb Source Type: research
Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis
CONCLUSIONS: Clinicians could use these factors to consider more aggressive treatment regimens for those at highest risk of early relapse.PMID:37393121 | DOI:10.1016/j.clml.2023.06.002
Source: Clinical Lymphoma and Myeloma - July 1, 2023 Category: Cancer & Oncology Authors: Salomon Manier Meletios Dimopoulos Cyrille Hulin Xavier Leleu Michel Delforge Katja Weisel Jorge Mouro Bruno Costa Michael Sturniolo Thierry Facon Source Type: research
